Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorBabl, Franz E
dc.contributor.authorHerd, David
dc.contributor.authorBorland, Meredith
dc.contributor.authorKochar, Amit
dc.contributor.authorLawton, Ben
dc.contributor.authorHort, Jason
dc.contributor.authorWest, Adam
dc.contributor.authorGeorge, Shane
dc.contributor.authorZhang, Michael
dc.contributor.authorVelusamy, Karthik
dc.contributor.authorSullivan, Frank
dc.contributor.authorOakley, Ed
dc.contributor.authorDavidson, Andrew
dc.contributor.authorHopper, Sandy M
dc.contributor.authorCheek, John A
dc.contributor.authorBerkowitz, Robert
dc.contributor.authorHearps, Stephen
dc.contributor.authorWilson, Catherine L
dc.contributor.authorWilliams, Amanda
dc.contributor.authorElborough, Hannah
dc.contributor.authorLegg, Donna
dc.contributor.authorPharm, B
dc.contributor.authorMackay, Mark T
dc.contributor.authorLee, Katherine J
dc.contributor.authorDalziel, Stuart R
dc.contributor.authorPaediatric Research in Emergency Departments International Collaborative (PREDICT)
dc.date.accessioned2023-08-24T23:40:01Z
dc.date.available2023-08-24T23:40:01Z
dc.date.issued2022-11-15
dc.identifier281076889
dc.identifier867799a2-c9a1-41bd-ab31-b2f870a707a3
dc.identifier36008143
dc.identifier85142901384
dc.identifier000886237100020
dc.identifier.citationBabl , F E , Herd , D , Borland , M , Kochar , A , Lawton , B , Hort , J , West , A , George , S , Zhang , M , Velusamy , K , Sullivan , F , Oakley , E , Davidson , A , Hopper , S M , Cheek , J A , Berkowitz , R , Hearps , S , Wilson , C L , Williams , A , Elborough , H , Legg , D , Pharm , B , Mackay , M T , Lee , K J , Dalziel , S R & Paediatric Research in Emergency Departments International Collaborative (PREDICT) 2022 , ' Efficacy of prednisolone for Bell palsy in children : a randomized, double-blind, placebo-controlled, multicenter trial ' , Neurology , vol. 99 , no. 20 , 201164 , pp. 2241-2252 . https://doi.org/10.1212/WNL.0000000000201164en
dc.identifier.issn0028-3878
dc.identifier.otherORCID: /0000-0002-6623-4964/work/118412084
dc.identifier.urihttps://hdl.handle.net/10023/28231
dc.descriptionFunding: The study was funded by a grant from the National Health and Medical Research Council (NHMRC, project grant GNT1078069), Canberra, Australia, the Emergency Medicine Foundation (EMSS-312R26-2016-GEORGE), Brisbane, Australia and the Perth Children’s Hospital Foundation project grant #9670, Perth, Australia. The PREDICT research network was part funded by an NHMRC Center of Research Excellence grant (GNT1058560), Canberra, Australia, the Murdoch Children’s Research Institute, Melbourne, Australia, and the Victorian Government’s Operational Infrastructure Support program. FEB’s time was part funded by a grant from the Royal Children’s Hospital Foundation, Melbourne, Victoria, Australia and an NHMRC Practitioner Fellowship. SRD’s time was part funded by the Health Research Council of New Zealand (HRC13/556) and Cure Kids, Auckland, New Zealand.en
dc.description.abstractBackground and Objective Corticosteroids are used to treat the early stages of idiopathic facial paralysis (Bell's palsy) in children, but their effectiveness is uncertain. We set out to determine if prednisolone improves the proportion of children with Bell's palsy with complete recovery at one month. Methods We conducted a double-blind, placebo-controlled, randomised trial of prednisolone in children presenting to emergency departments with Bell's palsy. Patients aged 6 months to less than 18 years, recruited within 72 hours after symptom onset, were randomly assigned to receive 10 days of treatment with oral prednisolone (approximately 1 mg/kg) or placebo. The primary outcome was complete recovery of facial function at 1 month rated on the House-Brackmann scale. Secondary outcomes included facial function, adverse events and pain up to 6 months. Target recruitment was n=540 (270 per group). Results Between 13 October 2015 to 23 August 2020, 187 children were randomised (94 to prednisolone and 93 to placebo) and included in the intention-to-treat analysis. At 1 month, the proportions of patients who had recovered facial function were 49% (n=43/87) in the prednisolone group compared with 57% (n=50/87) in the placebo group (risk difference -8.1%, 95% CI -22.8 to 6.7; adjusted odds ratio [aOR] 0.7, 95% CI 0.4 to 1.3). At 3 months these proportion were 90% (n=71/79) for the prednisolone group versus 85% (n=72/85) for the placebo group (risk difference 5.2%, 95%, CI -5.0 to 15.3; aOR 1.2, 95% CI 0.4 to 3.0) and at 6 months 99% (n=77/78) and 93% (n=76/82) respectively (risk difference 6.0%, 95% CI -0.1 to 12.2; aOR 3.0 95% CI 0.5 to 17.7) There were no serious adverse events and little evidence for group differences in secondary outcomes. Discussion In children with Bell's palsy the vast majority recover without treatment. The study, although underpowered, does not provide evidence that early treatment with prednisolone improves complete recovery.
dc.format.extent12
dc.format.extent377007
dc.language.isoeng
dc.relation.ispartofNeurologyen
dc.subjectRC0321 Neuroscience. Biological psychiatry. Neuropsychiatryen
dc.subjectRJ Pediatricsen
dc.subjectI-PWen
dc.subjectMCCen
dc.subject.lccRC0321en
dc.subject.lccRJen
dc.titleEfficacy of prednisolone for Bell palsy in children : a randomized, double-blind, placebo-controlled, multicenter trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews. Population and Behavioural Science Divisionen
dc.identifier.doi10.1212/WNL.0000000000201164
dc.description.statusPeer revieweden
dc.date.embargoedUntil2023-08-25


This item appears in the following Collection(s)

Show simple item record